Unexplained elevated maternal serum α-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes

American Journal of Obstetrics and Gynecology

Volumn 189, Issue 3, 2003, Pages 775-781

  Chandra, Sujata ^a,b,c   Scott, Heather ^b   Dodds, Linda ^b   Watts, Carolyn ^b   Blight, Claire ^b   Van Den Hof, Michiel ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

Author keywords

Complications; Pregnancy; Serum screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN;

ADULT; CANADA; CHROMOSOME ABERRATION; CONFERENCE PAPER; CONGENITAL MALFORMATION; CONTROLLED STUDY; DATA BASE; FEMALE; FETUS DEATH; GESTATIONAL AGE; HIGH RISK PATIENT; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOGISTIC REGRESSION ANALYSIS; MATERNAL SERUM; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURE LABOR; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SOLUTIO PLACENTAE;

EID: 0141859791     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0002-9378(03)00769-5     Document Type: Conference Paper

References (21)

1. Wilkins HL. Unexplained elevated maternal serum alpha-fetoprotein: what is the appropriate follow-up? Curr Opin Obstet Gynecol 1998;10:469-74.
2. Wenstrom KD, Owen J, Boots L, DuBard MB. Elevated second trimester human chorionic gonadotrophin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 1994;171:1038-41.
3. Benn PA, Horne D, Briganti S, Rodis JF, Clive JM. Elevated second trimester maternal serum hCG alone or in combination with elevated alpha-fetoprotein. Obstet Gynecol 1996;87:217-22.
4. Milunsky A, Jick SS, Bruell CL, MacLaughlin D, Tsung YK, Jick H, et al. Predictive values, relative risks, and overall benefits of high and low maternal serum α-fetoprotein screening in singleton pregnancies: new epidemiologic data. Am J Obstet Gynecol 1989;161:291-7.
5. Lieppman RE, Williams MA, Cheng EY, Resta R, Zingheim MN, Hickok DE, et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol 1993;168:1852-7.
6. Fair M, Cyr M, Allen AC, Wen SW, Guyon G, MacDonald RC. An assessment of the validity of a computer system for probabilistic record linkage of birth and infant death records in Canada: the Fetal and Infant Health Study Group. Chronic Dis Can 2000;21:8-13.
7. Waller DK, Lustig LS, Cunningham GC, Feuchtbaum LB, Hook EB. The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, pre-eclampsia, and placental complications. Obstet Gynecol 1996;88:816-22.
8. Konachuk PS, Bernstein IM, Capelen EL. Uterine artery Doppler velocimetry in the detection of adverse outcomes in women with unexplained elevated maternal serum α-fetoprotein levels. Am J Obstet Gynecol 1995;173:1115-9.
9. Sorensen TK, Williams MA, Zingheim RW, Clement SJ, Hickok DE. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol 1993;169:834-8.
10. Gonen R, Perez R, David M, Dar H, Merksamer R, Sharf M. The association between unexplained second-trimester maternal serum hCG elevation and pregnancy complications. Obstet Gynecol 1992;80:83-6.
11. Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high risk pregnancies. Prenat Diagn 1996;16:1129-35.
12. Mikic TS, Johnson P. Second trimester maternal serum beta human cborionic gonadotrophin and pregnancy outcome. BJOG 1999;106:598-600.
13. Morssink LP, de Wolf BT, Kornman LH, Beekhuis JR, van der Hall TP, Mantingh A. The relation berween serum markers in the second trimester and placental pathology: a study on extremely small for gestational age fetuses. BJOG 1996;103:779-83.
14. Berkeley AS, Killackey MA, Cederqvist LL. Elevated maternal serum α-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier. Am J Obstet Gynecol 1983;146:859-61.
15. Fox H. The effect of hypoxia on trophoblast in organ culture: a morphologic and autoradiologic study. Am J Obstet Gynecol 1970;107:1058-64.
16. American College of Obstetricians and Gynecologists. Maternal serum screening. Washington (DC): The College; 1996. Educational Bulletin No.: 228.
17. Huerta-Enochian G, Katz V, Erfurth S. The association of abnormal α-fetoprotein and adverse pregnancy outcome: does increased fetal surveillance affect pregnancy outcome? Am J Obstet Gynecol 2001;184:1549-53.
18. Burton BK. Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1988;72:709-13.
19. Bromley B, Frigoletto FD, Harlow BL, Pauker S, Benacerraf BR. The role of Boppler velocimetry in the structurally normal second-trimester fetus with elevated levels of maternal serum alpha-fetoprotein. Ultrasound Obstet Gynecol 1994;4:377-80.
20. van Rijn M, van der Schouw YT, Hagenaars AM, Visser GH, Christiaens GC. Adverse obstetric outcome in low- and high-risk pregnancies: predictive value of maternal serum screening. Obstet Gynecol 1999;94:929-34.
21. Waller DK, Lustig LS, Cunningham GC, Golbus MS, Hook EB. Second-trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death. N Engl J Med 1991;325:6-10.